[ad_1]
Johnson & Johnson JNJ Shares,
rose 0.9% on Monday, as the company nears early disclosure of interim results from an advanced clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December that it plans to share the results of the Phase 3 trial by the end of January, which would be the third company testing coronavirus vaccines in the United States to announce the results a closely monitored Phase 3 trial. The other two vaccines, developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Moderna Inc. MRNA,
are both mRNA-based vaccines that received emergency use clearance from the Food and Drug Administration in December. J&J said in December that it would file for emergency clearance for its experimental adenovirus vaccine in February if results are ready by the end of January. The company is expected to release its fourth quarter and full year results on Tuesday. J & J’s stock has gained 10.9% over the past year, while the S&P 500 SPX,
is up 15.6%.
[ad_2]
Source link